In an ideal world, yes, Wasa, but I don't think the cash injected via the recent dilution is sufficient to fund a proper Phase III trial, which would require upwards of US$300M in my estimation.
A positive announcement about taking PBT2 to the next stage of development is what we require now, and distressing as it might seem to shareholders who perceive Quintiles et al as getting a free lunch, this is commercial pragmatism in operation....management doing what it takes to move the product forward.
Alternate views welcomed.....
In an ideal world, yes, Wasa, but I don't think the cash...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $23.94M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $508 | 124.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 103 | 97947018 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179262 | 15 |
View Market Depth
| Last trade - 11.42am 25/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |